Haaruitval onderzoeken voor 2021, wat te verwachten?

Meer eerlijke en onafhankelijke informatie over haarproblemen door Hans J. Diks? 

Eenmaal per maand de laatste “haarweetjes”.

Van Haaruitval, Haartransplantatie tot Research, zonder reclame  https://www.haarproblemen.nl/haarweetjes/

Wat staat ons te wachten in 2021 op het gebied van onderzoeken in haaruitval problemen

Hierbij een aantal laboratoria die met deze materie bezig zijn. Vanwege de zorgvuldigheid in de oorspronkelijke Engelse taal. Gelukkig is dit voor de meeste van ons geen probleem. Wil je echter toch iets meer willen weten over een bepaald onderzoek mail me dat even op hans@haarproblemen.nl. Ik help je graag.

Clinical Hair Therapies In 2021

Samumed – The San Diego-based biotech with Turkish origins, Samumed, currently owns the furthest developed drug in the hair cure industry. Samumed’s wnt-activator SM04554 is undergoing a phase 3 clinical trial in Turkey with an estimated completion date of January 2021, according to its clinicaltrials.gov page. While the drug is not slated to be a powerhouse, it could be a valuable stacking treatment or alternative to current approved drugs for many folks if it becomes approved. Look for an update on SM04554 before summer 2021.

Breezula – This androgen-receptor-antagonist from Cassiopea is currently the second furthest developed drug in the hair growth industry. A phase 3 trial was anticipated to happen in 2020 but due to the unexpected occurences of 2020 the trial was delayed and is expected to commence in H1 2021. Cassiopea also has a phase 2 trial underway for female patients using Breezula which is expected to report data in Q2 2021.

Follicum – Another late-stage topical drug, FOL-005 from Follicum will be reporting important phase 2 trial results in Spring 2021. This trial is especially important for Follicum because it is the first time the peptide FOL-005 has been tested topically in androgenic alopecia patients. If results are favorable (around the 10% density improvement mark or better) there is a good chance that a larger industry partner will swoop in to take the drug into a pivotal phase 3 trial for market approval.

Shiseido/Replicel – The surprise follow-up trial of RCH-01 by Shiseido should be winding up in Q4 2021, though, it is not guaranteed that we will see its data next year. This time, the trial will involve multiple injections of dermal sheath cup cells over 12 months. Hopefully, meaningful results are seen this time around.

HairClone – Although HairClone is not technically offering a treatment themselves in 2021, it is mostly assured that the company will be ready to provide cultured/expanded dermal papilla cells to physicians in the UK who can use the cells to treat patients in 2021. A few timely government grants in 2020 were able to keep HairClone afloat and moving towards their goal of human application in 2021.

Kintor – As of December 29, 2020 Kintor has completed enrollment of a phase 2 clinical trial testing its androgen-receptor antagonist pyrilutamide in 120 male patients in China. The trial will involve multiple dosing cohorts and be carried out over a 6 month period. According to Kintor’s latest press release: “The Group expects to finalise the clinical study report (CSR) and release data for Phase II Clinical Trial in 2021 and commence a phase III clinical trial (for pyrilutamide) in the second half of 2021.” Kintor sounds awesome at this point, let’s hope they make good on their forecasts.

Stemson – While a clinical trial for Stemson in 2021is possible, it is more likely that we would get a timeline for a Stemson clinical trial at some point in 2021. Stemson is the only current active hair multiplication company based in the US and has recently pulled in a $7.5 million dollar investment from Allergan and a UK firm to get their program rolling ahead.

As you may have noticed, there certainly are other clinical stage companies we could hear from in 2021, such as J. Hewitt or Dr. Tsuji/Riken. However, at the moment I felt it best to keep the spotlight on the above listed companies.

Over The Counter Hair Therapies In 2021

Triple Hair TH16 – The all-natural OTC in Triple Hair’s pipeline, TH16, is expected to be released in Q1 2021 according to the company’s website. According to the company, in a self-sponsored clinical trial, TH16 outperformed 5% minoxidil in human patients. Though specific data numbers have not been disclosed, there were some decent looking photos shared in a Follicle Thought exclusive article. The main ingredients of TH16 are allegedly resveratrol and melatonin, two compounds that have shown to support hair growth in lab studies. The formula will be marketed to both men and women. Stay tuned for further updates direct from Triple Hair management in Q1 2021.

University of Wisconsin Hair Cap – Back in September 2019, news sprang from the University of Wisconsin that a unique new wearable device could become a new useful treatment for hair growth. The device gathers energy from its wearer’s daily movements and then outputs low-frequency pulses into the scalp to stimulate hair follicles. As the news was well received by many media outlets it was expected that a small university-based clinical trial would commence in 2020, but, due to widespread delays there was seemingly little to no progress made by Dr. Wang in getting his electrical hair cap into a human clinical trial. In my last communication with Dr. Wang in August 2020 he was still set on pursuing a trial for the cap as soon as it is tenable. Look for an update on a trial in H1 2021.

Bron: https://www.haarproblemen.nl/adviesraad

Bekijk ook: Haarprobleemonderzoeken